98480-31-0

Basic information

• Product Name: [1-(4-BROMO-PHENYL)-CYCLOPROPYL]-METHANOL
• Synonyms: [1-(4-BROMO-PHENYL)-CYCLOPROPYL]-METHANOL;1-(4-BroMophenyl)-1-cyclopropaneMethanol;1-(p-BroMophenyl)cyclopropaneMethanol
• CAS NO: 98480-31-0
• Molecular Formula: C₁₀H₁₁BrO
• Molecular Weight: 227.09774
• Product Categories: Aromatics;Inhibitors
• Mol File: 98480-31-0.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Storage Temp.: Room temperature.
• CAS DataBase Reference: [1-(4-BROMO-PHENYL)-CYCLOPROPYL]-METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: [1-(4-BROMO-PHENYL)-CYCLOPROPYL]-METHANOL(98480-31-0)
• EPA Substance Registry System: [1-(4-BROMO-PHENYL)-CYCLOPROPYL]-METHANOL(98480-31-0)

Safety Data

• Hazardous Substances Data: 98480-31-0(Hazardous Substances Data)

Usage

Description

[1-(4-BROMO-PHENYL)-CYCLOPROPYL]-METHANOL is an organic compound characterized by the presence of a cyclopropane ring attached to a methanol group and a 4-bromo-phenyl group. This unique molecular structure endows it with specific chemical properties that make it suitable for various applications, particularly in the pharmaceutical and chemical industries.

Uses

Used in Pharmaceutical Industry:
[1-(4-BROMO-PHENYL)-CYCLOPROPYL]-METHANOL is used as a key intermediate in the synthesis of amino acid derivatives, specifically as cathepsin cysteine protease inhibitors. These inhibitors play a crucial role in the development of therapeutic agents targeting various diseases, including cancer and neurodegenerative disorders. [1-(4-BROMO-PHENYL)-CYCLOPROPYL]-METHANOL's unique structure allows for the formation of potent and selective inhibitors, making it a valuable asset in drug discovery and development processes.

Upstream product

• 345965-52-8 1-(4-bromophenyl)cyclopropanecarboxylic acid 
• 16532-79-9 4-Bromophenylacetonitrile 
• 638220-35-6 1-(4-bromophenyl)-cyclopropanecarboxylic acid methyl ester 
• 124276-67-1 1-(4-bromophenyl)cyclopropanecarbonitrile 
• 6120-95-2 1-phenyl-1-cyclopropane carboxylic acid 

Downstream Products

• 1219741-77-1 methyl 5-[(6-chloro-5-{4-[1-(hydroxymethyl)cyclopropyl]phenyl}-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-benzimidazol-2-yl)oxy]-2-methylbenzoate 
• 1426925-13-4 1-(4-(2-chloro-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxylmethyl)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)cyclopropanecarbaldehyde O-methyl oxime 
• 1147531-61-0 1-(4-bromophenyl)cyclopropane-1-carbaldehyde 
• 1426925-14-5 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclopropane carbaldehyde 
• 1426925-15-6 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-(1-formyl cyclopropyl)benzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 1426925-16-7 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-((4-(1-(methoxyimino)methyl)cyclopropyl)benzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 1282659-26-0 [1-(4-bromophenyl)cyclopropyl]acetonitrile 
• 1620074-29-4 C₁₂H₁₃BrO₂ 
• 1620074-30-7 C₁₂H₁₅NO₂ 
• 1620074-31-8 C₁₂H₁₃IO₂ 
• 1620074-34-1 C₁₈H₂₅BO₄ 
• 1620074-35-2 C₃₁H₃₀N₂O₅ 
• 1620069-68-2 C₃₀H₂₈N₂O₅ 
• 1220219-36-2 (1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclopropyl)methanol 

Relevant articles and documents

Electrophilic Bromolactonization of Cyclopropyl Diesters Using Lewis Basic Chalcogenide Catalysts

An efficient and regioselective electrophilic bromolactonization of cyclopropylmethyl diesters using triphenylphosphine sulfide (Ph3PS) or diphenyl selenide (Ph2Se) as the Lewis basic chalcogenide catalyst has been developed. It was observed that Ph3PS favored the formation of anti-diastereomer and yielded the multi-functional γ-lactones. Interestingly, the diastereoselectivity was reversed when using Ph2Se as a catalyst where the syn-product instead of the anti-product was favored. (Figure presented.).

SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY

The present invention relates to compounds of formula (I), which have valuable pharmacological properties, in particular are activators of AMPK and which are therefore useful in the treatment of certain disorders that can be prevented or treated by activation of this receptor. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

NOVEL SGLT INHIBITORS

The present invention relates to novel compounds of Formula (I), their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the sy